- Home
- IMNM vs PNTG Comparison
IMNM vs PNTG Comparison
Compare IMNM & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- PNTG
- Stock Information
- Founded
- IMNM 2006
- PNTG 2019
- Country
- IMNM United States
- PNTG United States
- Employees
- IMNM N/A
- PNTG N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- PNTG Medical/Nursing Services
- Sector
- IMNM Health Care
- PNTG Health Care
- Exchange
- IMNM Nasdaq
- PNTG Nasdaq
- Market Cap
- IMNM 747.7M
- PNTG N/A
- IPO Year
- IMNM 2020
- PNTG N/A
- Fundamental
- Price
- IMNM $12.90
- PNTG $33.37
- Analyst Decision
- IMNM Strong Buy
- PNTG Buy
- Analyst Count
- IMNM 4
- PNTG 4
- Target Price
- IMNM $28.75
- PNTG $32.50
- AVG Volume (30 Days)
- IMNM 817.9K
- PNTG 386.0K
- Earning Date
- IMNM 11-07-2024
- PNTG 11-05-2024
- Dividend Yield
- IMNM N/A
- PNTG N/A
- EPS Growth
- IMNM N/A
- PNTG 53.90
- EPS
- IMNM N/A
- PNTG 0.64
- Revenue
- IMNM $10,784,000.00
- PNTG $611,806,000.00
- Revenue This Year
- IMNM N/A
- PNTG $27.04
- Revenue Next Year
- IMNM N/A
- PNTG $15.96
- P/E Ratio
- IMNM N/A
- PNTG $52.17
- Revenue Growth
- IMNM 62.73
- PNTG 21.93
- 52 Week Low
- IMNM $6.93
- PNTG $10.31
- 52 Week High
- IMNM $30.96
- PNTG $37.13
- Technical
- Relative Strength Index (RSI)
- IMNM 39.10
- PNTG 45.94
- Support Level
- IMNM $12.24
- PNTG $32.14
- Resistance Level
- IMNM $13.91
- PNTG $35.63
- Average True Range (ATR)
- IMNM 0.88
- PNTG 1.42
- MACD
- IMNM -0.23
- PNTG -0.44
- Stochastic Oscillator
- IMNM 15.31
- PNTG 17.67
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.